InSphero Appoints Distinguished Pharma Industry Executive Prof. Armin Wolf as Chief Scientific Officer
With 30 years of cumulative experience at Novartis and Janssen, Prof. Wolf strengthens InSphero leadership team and augments 3D model and organ-on-a-chip R&D. PDF Version
Schlieren, Switzerland – February 13, 2019 InSphero AG today announced that its Board of Directors has appointed Prof. Armin Wolf as Chief Scientific Officer (CSO) overseeing the company’s market leading 3D-cell-based organ-on-a-chip, metabolic disease, and toxicology programs.
An accomplished pharmaceutical R&D executive and board-certified toxicologist, Prof. Wolf brings a first-hand perspective on the challenges facing industry and the need for more physiologically relevant human models to improve efficiency in drug discovery and safety testing.
“With their 3D human tissue platforms and organ-on-a-chip technology, InSphero is an innovative partner for an industry in need of new ways to improve productivity and return on R&D investment,” noted Prof. Wolf. “After many years in industry, I’m excited to join this impressive team and continue advancement of these technologies to better support pharmaceutical companies in their quest for new cures.”
Prof. Wolf joins the company from Janssen Pharmaceuticals Inc. (a Johnson & Johnson company), where he was Senior Director and Global Head of the Mechanistic & Investigative Toxicology (MIT) group in Beerse (Belgium), Spring House (PA) and La Jolla (CA). Previously, Prof. Wolf led Novartis drug development teams as Director of Global Biomarker Group and as Head of Biochemical Cellular Toxicology in Discovery and Investigative Toxicology in Basel. Prof. Wolf will continue his role as Professor of Toxicology at the Technical University of Kaiserslautern, Germany,
In March, Dr. Patrick Guye, who has successfully led InSphero R&D and assay services as CSO over the past two years, will join the company’s Scientific Advisory Board. Speaking on behalf of the InSphero Board and executive management team, CEO and Co-founder Dr. Jan Lichtenberg says, “Patrick has been instrumental in guiding InSphero towards becoming the leading technology provider for predictive, human, 3D in vitro disease models that help pharma companies identify new drug targets and therapies for complex diseases such as NASH and type 1 and type 2 diabetes. We have greatly appreciated his innovative spirit and market insights, and we are grateful that he will continue to contribute as a member of our Scientific Advisory Board.”
For more information about InSphero, visit insphero.com.
###
InSphero contacts
Dr. Jan Lichtenberg
Chief Executive Officer
Phone +41 44 5150490
[email protected]
About InSphero
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding healthy and diseased human physiology in vitro. The company’s robust, precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero specializes in solutions for liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology, which underlies these 3D InSight™ Discovery and Safety Platforms, includes 96- and 384-well plate formats as well as the Akura™ Flow organ-on-a-chip system. Together, InSphero platforms and technologies are designed to drive efficient innovation throughout all phases of drug development.
For more information, visit insphero.com.
Follow us on Twitter and LinkedIn.
Images
